Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on January 15, 2026, reporting events that occurred on January 9, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "COCP".
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on equity compensation arrangements.
Material Changes and Events
On January 9, 2026, the Compensation Committee approved the grant of non-qualified stock options under the 2025 Equity Incentive Plan to directors, executive officers, and a consultant. Key terms include:
- Exercise Price: Closing price of January 8, 2026.
- Term: 10 years.
- Vesting Schedule: 50% vests on January 9, 2027; the remaining 50% vests in eight equal quarterly installments starting March 31, 2027, contingent on continued service.
A summary of grants is provided below:
| Recipient | Role | Total Options Granted |
|---|---|---|
| Dr. Roger Kornberg | Director | 24,615 |
| Dr. Philip Frost | Director | 24,615 |
| Steve Rubin | Director | 16,410 |
| Fred Hassan | Director | 16,410 |
| Richard Pfenniger | Director | 16,410 |
| Anthony Japour | Director | 16,410 |
| James Martin | Officer (CFO/Co-CEO) | 49,229 |
| Sam Lee | Officer | 49,229 |
| Consultant | Consultant | 40,000 |
Additionally, the Committee approved a $50,000 cash award to Dr. Roger Kornberg for his service as chairman of the Scientific Advisory Board.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of risks and contingencies beyond the standard vesting conditions tied to continued service.
Investor Verification Checklist
- Verify the closing stock price on January 8, 2026, to determine the exercise price of the granted options.
- Review the Company's 2025 Equity Incentive Plan to confirm the total pool of shares available for future grants.
- Monitor future filings for the execution of the Non-Qualified Stock Option Agreements.
- Assess the dilution impact of the total 282,318 options granted in this transaction.